Товецимиг

Prop. INN (наименование, предложенное ВОЗ)

2923284-73-3

immunoglobulin G1-scFvlh_L-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)] and anti-[Homo sapiens DLL4 (delta-like 4)], humanized and Homo sapiens monoclonal antibody; bispecific;
H-gamma1 heavy chain anti-VEGFA fused to a scFvlh anti-DLL4 (1-714) [H-gamma1 heavy chain anti-VEGFA humanized (1-453) [VH (Homo sapiens IGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.9.16] (26-33.51-59.97-112)) (1-123) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14 (CH1 R120>K (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)] -15-mer tris(tetraglycyl-seryl) linker (454-468) -scFvlh anti-DLL4 Homo sapiens (469-714) [V-LAMBDA (Homo sapiens IGLV1-47*02 (89.7%) -IGLJ2*01 (90.9%) G120>C (571), CDR-IMGT [8.3.11] (494-501.519-521.558-568)) (469-578) -20-mer tetrakis(tetraglycyl-seryl) linker (579-598) -VH (Homo sapiens IGHV3-23*03 (91.8%) -IGHD -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (624-631.649-656.695-703)) (599-714)]]; (226-214’)-disulfide with L-kappa light chain anti-VEGFA humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (88.4%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa

Поделиться этой страницей